howdy joe, the wisdom of immuteps collaboration with Merck which enables it to have total ownership
of EFTI may well turn out to be a masterstroke. As time goes by keytruda is showing more and more signs
of not being the dominating monotherapy treatment it once was. EFTI, if it continues it's current trajectory
may well turn out to be a very valuable commodity indeed....
2024 catalysts left, page-21
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.010(3.08%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.0¢ | $584.2K | 1.787M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 311433 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 113721 | 6 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |